Cloud-Clone unveils DHT assay kit for androgen research

Cloud-Clone Corp. has released a technical overview and a competitive-ELISA kit for dihydrotestosterone, aiming to help researchers measure the androgen more reliably across human, mouse and rat samples. The move targets a long-running lab problem: DHT is biologically important, but low concentrations, cross-reactivity and sample instability make it difficult to quantify accurately.

Why it matters: - Dihydrotestosterone is linked to hair loss, prostate disease, acne, PCOS, metabolism and reproductive biology, so better measurement tools affect a wide range of preclinical and translational studies. - Reliable DHT data can improve animal-model research and candidate-drug testing by reducing false readings and batch-to-batch variation. - The release addresses a common bottleneck in androgen research: many labs can study DHT biology, but fewer can measure it consistently in real samples.

What happened: - Cloud-Clone Corp. released a technical overview on DHT biology and detection methods. - Cloud-Clone Corp. also introduced a competitive-ELISA kit for dihydrotestosterone, Catalog No. CEA443Ge. - The kit is validated for human, mouse and rat matrices. - The company positioned the product for academic labs, research institutions and translational facilities worldwide.

The details: - DHT is produced when 5α-reductase converts testosterone in peripheral tissues. - DHT binds the androgen receptor with about 25-fold higher affinity than testosterone. - Skin, prostate, sebaceous glands, hair follicles and adipose tissue show high 5α-reductase expression. - Local DHT production helps explain why normal circulating testosterone can still coincide with alopecia or acne. - DHT supports male external genital development during embryogenesis. - In adulthood, DHT helps maintain prostate tissue, sebaceous gland activity, body-hair patterning and skeletal muscle mass. - Females also produce physiologically relevant DHT from ovarian- and adrenal-derived testosterone. - Excess DHT is associated with androgenetic alopecia, benign prostatic hyperplasia, severe acne and seborrheic dermatitis in males. - Elevated DHT is described as a key marker in PCOS, alongside hirsutism, refractory acne and ovulatory dysfunction. - Low DHT may contribute to gonadal developmental defects, reduced libido and loss of skeletal-muscle mass. - DHT research also connects to fat redistribution, insulin sensitivity, cardiovascular homeostasis and some hormone-dependent tumors. - DHT is difficult to measure because it often appears at pg-to-ng concentrations and is vulnerable to cross-reactivity from testosterone and androstenedione. - Many commercial assays were built for human serum and can perform poorly in mouse and rat samples. - DHT can adsorb to tube surfaces, and freeze-thaw cycles or poor storage can reduce analyte levels. - Researchers often see replicate variation, inconsistent batch results and weak statistical separation between groups. - LC-MS/MS remains the gold-standard method because it separates similar steroids and identifies them by mass-to-charge ratio. - LC-MS/MS can quantify multiple steroid molecules in one run, but it is costly, slow and labor-intensive for large cohorts. - Radioimmunoassay offers sensitivity, but radioactive handling, short reagent shelf life and administrative burden limit its use. - Competitive-ELISA is the most common basic-science option because it uses standard microplate readers and supports higher throughput. - Competitive-ELISA performance depends heavily on antibody quality, cross-reactivity control and tight intra-assay and inter-assay variation. - The Cloud-Clone kit is designed to lower cross-reactivity and control intra- and inter-batch variation. - The kit supports serum, plasma and tissue-homogenate samples. - The kit is intended for androgen-mechanism studies, in-vivo drug efficacy evaluation and phenotypic analysis of animal disease models. - The company lists use cases in urology, dermatology, endocrine metabolism, pharmacology, reproductive biology and metabolic research. - The company also says the product can support 5α-reductase inhibitor testing and androgen-receptor modulator studies.

Between the lines: - The release is as much about workflow as biology: Cloud-Clone is arguing that the main barrier in DHT research is not a lack of scientific interest, but a lack of reproducible assays. - The company is also framing LC-MS/MS and competitive-ELISA as complementary tools rather than competing replacements, depending on sample volume and lab resources. - The broader message is that androgen research is moving toward more layered designs, with DHT measured alongside testosterone and SHBG to better separate total hormone levels from bioavailable hormone.

What's next: - Researchers are likely to use the kit in animal models studying prostate disease, alopecia, acne, PCOS, insulin resistance and hormone-targeting therapies. - Cloud-Clone says future work may focus on 5α-reductase isoforms, adipocyte biology, sex differences in androgen signaling and improved sample handling. - The company says it will continue refining steroid-hormone assay tools to support mechanistic research and pre-clinical drug evaluation.

The bottom line: - DHT is emerging as a broader biomarker than a hair-loss trigger, and Cloud-Clone is betting that better assay design will expand what researchers can confidently study.**